| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 38,935 | 34,367 | ||
| Marketable securities | 51,281 | 66,482 | ||
| Prepaid expenses and other current assets | 4,285 | 3,853 | ||
| Total current assets | 94,501 | 104,702 | ||
| Property and equipment, net | 2,175 | 2,407 | ||
| Operating lease right-of-use asset | 1,050 | 1,340 | ||
| Other assets | 0 | 674 | ||
| Total assets | 97,726 | 109,123 | ||
| Accounts payable | 911 | 1,157 | ||
| Accrued and other current liabilities | 3,927 | 4,107 | ||
| Operating lease liabilities, current | 3,259 | 3,808 | ||
| Debt, current | 5,279 | 5,293 | ||
| Total current liabilities | 13,376 | 14,365 | ||
| Operating lease liabilities, noncurrent | 0 | 344 | ||
| Debt, noncurrent | 1,374 | 2,628 | ||
| Total liabilities | 14,750 | 17,337 | ||
| Common stock, 0.001 par value, 250,000,000 shares authorized as of september30, 2025 (unaudited) and december31, 2024 7,323,106 and 7,303,629 shares issued and outstanding as of september30, 2025 (unaudited) and december31, 2024, respectively | 7 | 7 | ||
| Additional paid-in capital | 558,941 | 556,805 | ||
| Accumulated other comprehensive income (loss) | 14 | -267 | ||
| Accumulated deficit | -475,986 | -464,759 | ||
| Total stockholders' equity | 82,976 | 91,786 | ||
| Total liabilities and stockholders' equity | 97,726 | 109,123 | ||
Kezar Life Sciences, Inc. (KZR)
Kezar Life Sciences, Inc. (KZR)